LH - Nothing Compelling About Natera

• Shares of diagnostic testing concern Natera are down 70% from their all-time high set in September 2021, as the biotech sector and high-growth no-profit names get pummeled.
• Additionally, the company is dogged by allegations of fraudulent and unethical marketing practices, included in a short report from Hindenburg Research.
• Projected to grow its topline 29% and 24% in FY22 and FY23, the recent insider buying into this significantly unprofitable concern merited a deeper dive.
• The stock recently became subject to speculation that an activist investor may take a stake in the firm. A full investment analysis follows in the paragraphs below.

For further details see: